Background: Sepsis is a potentially fatal systemic inflammatory response syndrome (SIRS) that threatens millions of lives worldwide. Echinococcus granulosus antigen B (EgAgB) is a protein released by the larvae of the tapeworm. This protein has been shown to play an important role in modulating host immune response. In this study we expressed EgAgB as soluble recombinant protein in E. coli (rEgAgB) and explored its protective effect on sepsis. Methods: The sepsis model was established by cecal ligation and puncture (CLP) procedure in BALB/c mice. The therapeutic effect of rEgAgB on sepsis was performed by interperitoneally injecting 5 µg rEgAgB in mice with CLP-induced sepsis and observing the 72 h survival rate after onset of sepsis. The proinflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-6] and regulatory cytokines [IL-10, transforming growth factor beta (TGF-β)] were measured in sera, and the histopathological change was observed in livers, kidneys, and lungs of septic mice treated with rEgAgB compared with untreated mice. The effect of rEgAgB on the macrophage polarization was performed in vitro by incubating rEgAgB with peritoneal macrophages. The levels of TLR2 and MyD88 were measured in these tissues to determine the involvement of TLR-2/MyD88 in the sepsis-induced inflammatory signaling pathway. Results: In vivo, we observed that treatment with rEgAgB significantly increased the survival rate of mice with CLP-induced sepsis up to 72 h while all mice without treatment died within the same period. The increased survival was associated with reduced pathological damage in key organs such as liver, lung, and kidneys. It was supported by the reduced proinflammatory cytokine levels and increased regulatory cytokine expression in peripheral blood and key organ tissues. Further study identified that treatment with rEgAgB promoted macrophage polarization from classically activated macrophage (M1) to regulatory M2-like macrophage via inhibiting TLR2/MyD88 signal pathway. Conclusions: The therapeutic effects of rEgAgB on mice with sepsis was observed in a mice model that was associated with reduced inflammatory responses and increased regulatory responses, possibly through inducing polarization of macrophages from proinflammatory M1 to regulatory M2 phenotype through inhibiting TLR2/MyD88 inflammatory pathway. Graphical
Sepsis is a disease caused by multiple microbial infections resulting in multiple organ failure. Schistosoma japonicum secreted cystatin (Sj‐Cys) is a strong immunomodulator that stimulates M2 macrophages and alleviates inflammatory damage caused by sepsis. To determine whether the therapeutic effect of Sj‐Cys on sepsis can be conveyed by the exosomes released by Sj‐Cys‐stimulated macrophages, RAW264.7 macrophages were stimulated with rSj‐Cys in vitro, the exosomes were obtained from the cell culture supernatant by ultracentrifugation. Sepsis was induced in BALB/c mice by cecal ligation and puncture (CLP). The septic mice were treated with exosomes derived from Sj‐Cys‐treated macrophages. The treatment effect of exosomes on sepsis was assessed by examining the survival rate of mice up to 72 hr and measuring serum levels of inflammatory cytokines, liver/kidney damage biomarkers, and observing pathological changes in tissue sections. The tissue levels of M1, M2 macrophage surface markers, and TRL2/MyD88 were measured to explore possible mechanisms. Results. Exosomes derived from Sj‐Cys‐treated macrophages exhibited significant therapeutic effect on CLP‐induced sepsis in mice with prolonged survival rate and less damage of critical organs by downregulating the proinflammatory factors TNF‐α and IL‐6 and upregulating the anti‐inflammatory factor TGF‐β. The therapeutic effect of exosomes is associated with macrophage polarization from M1 to M2 in the infected tissues via downregulating TRL2/MyD88 inflammatory pathway. Conclusions. Exosomes derived from Sj‐Cys‐treated macrophages attenuated sepsis in mice through promoting macrophage polarization from M1 to M2 and reducing inflammatory responses, possibly via downregulating TLR2/MyD88 inflammatory signaling pathway. This offers new approaches for immunotherapy of sepsis.
Background: Myocardial ischemia–reperfusion (IR) injury is a critical complication in patients with myocardial infarction following the restoration of coronary blood flow. Echinococcus granulosus cyst fluid protein antigen B ( Eg AgB) is known to modulate host immune response. This study investigates whether the recombinant antigen B subunit 2 (r Eg AgB8/2) can mitigate IR injury by suppressing inflammation and promoting myocardial tissue repair. Methods: An IR injury model was induced by ligating the left anterior descending (LAD) coronary artery for 1 h, followed by 24 h reperfusion. Recombinant Eg AgB8/2 protein expressed in E. coli was administered intraperitoneally at the onset of reperfusion to evaluate its therapeutic potential. After 24 h of reperfusion, cardiac function and injury were assessed using echocardiography, TTC/Evans Blue staining, and histopathological analysis. Protein and mRNA levels of cytokines (TNF-α, IL-6, IL-10, and TGF-β) in sera and cardiac tissue were quantified using ELISA and RT-qPCR, respectively. In vitro studies, cytokine secretion in bone marrow-derived macrophages (BMDMs) culture supernatants was measured by ELISA. Macrophage polarization was evaluated via flow cytometry by identifying surface markers for M1 (CD86⁺) and M2 (CD206⁺) phenotypes. Expression levels of proteins in the cGAS/STING/p-TBK1/p-IRF3 signaling pathway in both myocardial tissues and BMDMs were detected by Western blotting. Results: Treatment with r Eg AgB8/2 significantly improved cardiac function and reduced myocardial injury markers (LDH, CK-MB) and infarct size in mice with IR injury. Compared to untreated IR controls, r Eg AgB8/2 treatment significantly reduced the levels of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) in both serum and cardiac tissue, and downregulated the M1 macrophage marker iNOS in cardiac tissue. Concurrently, it increased the expression of anti-inflammatory cytokines (IL-10 and TGF-β) in serum and cardiac tissue, along with upregulating the M2 macrophage marker Arg-1 in cardiac tissue. This reduction in the inflammatory response in IR-injured cardiac tissue was associated with enhanced polarization toward the M2 macrophage phenotype. In vitro studies further showed that r Eg AgB8/2 promotes M2 macrophage polarization associated with reduced activation of the cGAS/STING/TBK1/IRF3 signaling pathway. Conclusions: r Eg AgB8/2 promotes macrophage polarization toward M2 phenotype in a manner associated with suppression of the cGAS/STING/TBK1/IRF3 signaling pathway to attenuate myocardial IR injury and associated inflammation. It provides a novel therapeutic strategy for ischemia–reperfusion injury and related inflammatory diseases.